Literature DB >> 21191012

The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Natasha M Girgis1, Brian C Dehaven, Yuhong Xiao, Edward Alexander, Kendra M Viner, Stuart N Isaacs.   

Abstract

Complement activation is an important component of the innate immune response against viral infection and also shapes adaptive immune responses. Despite compelling evidence that complement activation enhances T cell and antibody (Ab) responses during viral infection, it is unknown whether inhibition of complement by pathogens alters these responses. Vaccinia virus (VACV) modulates complement activation by encoding a complement regulatory protein called the vaccinia virus complement control protein (VCP). Although VCP has been described as a virulence factor, the mechanisms by which VCP enhances VACV pathogenesis have not been fully defined. Since complement is necessary for optimal adaptive immune responses to several viruses, we hypothesized that VCP contributes to pathogenesis by modulating anti-VACV T cell and Ab responses. In this study, we used an intradermal model of VACV infection to compare pathogenesis of wild-type virus (vv-VCPwt) and a virus lacking VCP (vv-VCPko). vv-VCPko formed smaller lesions in wild-type mice but not in complement-deficient mice. Attenuation of vv-VCPko correlated with increased accumulation of T cells at the site of infection, enhanced neutralizing antibody responses, and reduced viral titers. Importantly, depleting CD8(+) T cells together with CD4(+) T cells, which also eliminated T helper cell-dependent Ab responses, restored vv-VCPko to wild-type levels of virulence. These results suggest that VCP contributes to virulence by dampening both antibody and T cell responses. This work provides insight into how modulation of complement by poxviruses contributes to virulence and demonstrates that a pathogen-encoded complement regulatory protein can modulate adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191012      PMCID: PMC3067952          DOI: 10.1128/JVI.01474-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

Review 1.  Complement. Second of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

Review 2.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

3.  Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment.

Authors:  R F Tsuji; I Kawikova; R Ramabhadran; M Akahira-Azuma; D Taub; T E Hugli; C Gerard; P W Askenase
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

4.  Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement.

Authors:  Ariella M Rosengard; Yu Liu; Zhiping Nie; Robert Jimenez
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Humoral response to herpes simplex virus is complement-dependent.

Authors:  X J Da Costa; M A Brockman; E Alicot; M Ma; M B Fischer; X Zhou; D M Knipe; M C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Macrophage-derived complement component C4 can restore humoral immunity in C4-deficient mice.

Authors:  Mihaela Gadjeva; Admar Verschoor; Mark A Brockman; Heather Jezak; Li Ming Shen; David M Knipe; Michael C Carroll
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

7.  Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection.

Authors:  A Verschoor; M A Brockman; D M Knipe; M C Carroll
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

8.  Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection.

Authors:  Manfred Kopf; Brian Abel; Awen Gallimore; Michael Carroll; Martin F Bachmann
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

9.  Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection.

Authors:  Admar Verschoor; Mark A Brockman; Mihaela Gadjeva; David M Knipe; Michael C Carroll
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

Review 10.  The relevance of complement to virus biology.

Authors:  Clare E Blue; O Brad Spiller; David J Blackbourn
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  19 in total

1.  Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo.

Authors:  Chengliang Zhu; Hui Song; Fengxia Xu; Wei Yi; Fang Liu; Xinghui Liu
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

2.  Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection.

Authors:  Ryan D Estep; Ilhem Messaoudi; Megan A O'Connor; Helen Li; Jerald Sprague; Alexander Barron; Flora Engelmann; Bonnie Yen; Michael F Powers; John M Jones; Bridget A Robinson; Beata U Orzechowska; Minsha Manoharan; Alfred Legasse; Shannon Planer; Jennifer Wilk; Michael K Axthelm; Scott W Wong
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 3.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

4.  Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.

Authors:  Christine Pugh; Sarah Keasey; Lawrence Korman; Phillip R Pittman; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

5.  Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity.

Authors:  John Bernet; Muzammil Ahmad; Jayati Mullick; Yogesh Panse; Akhilesh K Singh; Pradeep B Parab; Arvind Sahu
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 4.169

6.  Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.

Authors:  Jitendra Kumar; Viveka Nand Yadav; Swastik Phulera; Ashish Kamble; Avneesh Kumar Gautam; Hemendra Singh Panwar; Arvind Sahu
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

7.  Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.

Authors:  Clement A Meseda; Jordan Kuhn; Vajini Atukorale; Joseph Campbell; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2014-07-16

Review 8.  Drivers and regulators of humoral innate immune responses to infection and cancer.

Authors:  Deepak Kumar; Yeni Romero; Kaitlynn N Schuck; Haley Smalley; Bibek Subedi; Sherry D Fleming
Journal:  Mol Immunol       Date:  2020-03-18       Impact factor: 4.407

Review 9.  Poxviruses and the evolution of host range and virulence.

Authors:  Sherry L Haller; Chen Peng; Grant McFadden; Stefan Rothenburg
Journal:  Infect Genet Evol       Date:  2013-10-24       Impact factor: 3.342

10.  Elucidating the role of the complement control protein in monkeypox pathogenicity.

Authors:  Paul N Hudson; Joshua Self; Sonja Weiss; Zachary Braden; Yuhong Xiao; Natasha M Girgis; Ginny Emerson; Christine Hughes; Scott A Sammons; Stuart N Isaacs; Inger K Damon; Victoria A Olson
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.